Global Parkinson's Disease Market to Drop by $0.5 Billion by 2019, Says Report
The global Parkinson’s Disease market will decline from $3.4 billion in 2012 to $2.9 billion by 2019 (a negative Compound Annual Growth Rate of 2.3%), according to a new report by GBI Research (New York, NY).
The global Parkinson’s Disease market will decline from $3.4 billion in 2012 to $2.9 billion by 2019 (a negative Compound Annual Growth Rate of 2.3%), according to a new report by GBI Research (New York, NY).
With PD drugs such as Azilect (rasagiline mesylate), Stalevo (levodopa, carbidopa, entacapone) and Comtan (entacapone) set to lose their patents by the end of the forecast period, even the approval and launch of late-stage pipeline drugs for PD, including Rytary, safinamide and pimavanserin, “won’t be significant enough to diminish the impact of generic erosion,” says GBI Research Analyst Angel Wong.
However, disease-modifying treatment for PD remains an urgent unmet need. But with 87% of neuroprotective treatments still in early-stage development, these medications face several challenges, not least “the need for a reliable biomarker that can accelerate such development,” adds Wong.
To access the GBI Research report, click here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
